KRAS and neoplasm: Both GC1118 (TGII = −36.8%, p = 0.0053) and cetuximab (TGII = −29.4%, p = 0.006) induced complete tumor regression in CRC-003T PDXs (KRAS-wild-type; high-affinity ligand, 77.2%; low-affinity ligand, 22.8%) (GC1118 vs. cetuximab, p = 0.09; Figure 3A, upper panel and Table S2).